For the quarter ending 2025-09-30, COLL had $32,752K increase in cash & cash equivalents over the period. $78,250K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Product revenues, net | 209,361 | - |
| Cost of product revenues (excluding intangible asset amortization) | 24,717 | - |
| Intangible asset amortization and impairment | 55,473 | - |
| Commercial expenses | 36,931 | - |
| Corporate expenses | 10,905 | - |
| Medical expenses | 7,775 | - |
| Technical operations expenses | 129 | - |
| Stock-based compensation expense | 9,811 | - |
| Other segment items | 1,533 | - |
| Interest expense | 21,767 | - |
| Interest income | 12,332 | - |
| Provision for income taxes | 11,929 | - |
| Net income | 31,507 | 14,400 |
| Amortization expense | 55,473 | 110,946 |
| Depreciation expense | 1,033 | 2,226 |
| Deferred income taxes | -12,132 | -3,453 |
| Stock-based compensation expense | 9,811 | 22,342 |
| Non-cash lease expense (benefit) | 503 | -60 |
| Non-cash interest expense for amortization of debt discount and issuance costs | 1,343 | 2,722 |
| Net accretion for deferred royalty obligation | -348 | 2,014 |
| Net amortization of premiums and discounts on investments | 230 | 588 |
| Change in fair value of contingent consideration | -19 | -1,144 |
| Accounts receivable | 20,926 | -15,509 |
| Inventory | -96 | 2,588 |
| Prepaid expenses and other assets | -21,337 | 21,120 |
| Accounts payable | -3,283 | 6,956 |
| Accrued liabilities | -8,114 | -12,086 |
| Accrued rebates, returns and discounts | 2,432 | -8,239 |
| Operating lease assets and liabilities | 10 | - |
| Deferred revenue | -55 | - |
| Net cash provided by operating activities | 78,438 | 127,837 |
| Purchases of property and equipment | 188 | 863 |
| Purchases of marketable securities | 45,245 | 42,501 |
| Maturities of marketable securities | 14,565 | 30,769 |
| Net cash used in investing activities | -30,868 | -12,595 |
| Proceeds from issuances of common stock from employee stock purchase plan | 857 | 506 |
| Proceeds from the exercise of stock options | 1,435 | 1,860 |
| Payments made for employee stock tax withholdings | 964 | 11,021 |
| Repurchases of common stock, including the asr agreement | 0 | 25,104 |
| Repayment of term notes | 16,146 | 32,292 |
| Payments made for deferred purchase price for acquisition | 0 | 7,555 |
| Net cash used in financing activities | -14,818 | -73,606 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 32,752 | 41,636 |
| Cash and cash equivalents at beginning of period | 96,612 | - |
| Cash and cash equivalents at end of period | 171,000 | - |
COLLEGIUM PHARMACEUTICAL, INC (COLL)
COLLEGIUM PHARMACEUTICAL, INC (COLL)